Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    European urology. 2013 Jul 10. pii: S0302-2838(13)00663-5. doi: 10.1016/j.eururo.2013.06.048
    Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
    Tilki D1,  Nguyen HG2,  Dall'Era MA3,  Bertini R4,  Carballido JA5,  Chromecki T6,  Ciancio G7,  Daneshmand S8,  Gontero P9,  Gonzalez J10,  Haferkamp A11,  Hohenfellner M12,  Huang WC13,  Koppie TM14,  Lorentz CA15,  Mandel P16,  Martinez-Salamanca JI17,  Master VA18,  Matloob R19,  McKiernan JM20,  Mlynarczyk CM21,  Montorsi F22,  Novara G23,  Pahernik S24,  Palou J25,  Pruthi RS26,  Ramaswamy K27,  Rodriguez Faba O28,  Russo P29,  Shariat SF30,  Spahn M31,  Terrone C32,  Vergho D33,  Wallen EM34,  Xylinas E35,  Zigeuner R36,  Libertino JA37,  Evans CP38
    Author information
    1Department of Urology, University of California, Davis, School of Medicine, Sacramento, CA, USA. Electronic address: derya.tilki@ucdmc.ucdavis.edu.
    2Department of Urology, University of California, Davis, School of Medicine, Sacramento, CA, USA.
    3Department of Urology, University of California, Davis, School of Medicine, Sacramento, CA, USA.
    4Department of Urology, Hospital San Raffaele, University Vita-Salute, Milan, Italy.
    5Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain.
    6Department of Urology, Medical University of Graz, Graz, Austria.
    7Miami Transplant Institute, University of Miami, Miami, FL, USA.
    8USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
    9Department of Urology, A.O.U. San Giovanni Battista, University of Turin, Turin, Italy.
    10Department of Urology, Getafe University Hospital, Madrid, Spain.
    11Department of Urology, University of Frankfurt, Frankfurt, Germany.
    12Department of Urology, University of Heidelberg, Heidelberg, Germany.
    13Department of Urology, New York University School of Medicine, New York, NY, USA.
    14Department of Urology, Oregon Health & Science University, Portland, OR, USA.
    15Department of Urology, Emory University, Atlanta, GA, USA.
    16Institute of Empirical Economic Research, University of Leipzig, Leipzig, Germany.
    17Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain.
    18Department of Urology, Emory University, Atlanta, GA, USA.
    19Department of Urology, Hospital San Raffaele, University Vita-Salute, Milan, Italy.
    20Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
    21Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
    22Department of Urology, Hospital San Raffaele, University Vita-Salute, Milan, Italy.
    23University of Padua, Padua, Italy.
    24Department of Urology, University of Heidelberg, Heidelberg, Germany.
    25Department of Urology, Fundació Puigvert, Barcelona, Spain.
    26Department of Urology, UNC at Chapel Hill, Chapel Hill, NC, USA.
    27Department of Urology, New York University School of Medicine, New York, NY, USA.
    28Department of Urology, Fundació Puigvert, Barcelona, Spain.
    29Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    30Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
    31University of Würzburg, Würzburg, Germany.
    32Division of Urology, Maggiore della Carita Hospital, University of Eastern Piedmont, Novara, Italy.
    33University of Würzburg, Würzburg, Germany.
    34Department of Urology, UNC at Chapel Hill, Chapel Hill, NC, USA.
    35Department of Urology, Weill Cornell Medical Center, New York, NY, USA.
    36Department of Urology, Medical University of Graz, Graz, Austria.
    37Department of Urology, Lahey Clinic, Burlington, MA, USA.
    38Department of Urology, University of California, Davis, School of Medicine, Sacramento, CA, USA.
    Abstract

    BACKGROUND: Although different prognostic factors for patients with renal cell carcinoma (RCC) and vena cava tumor thrombus (TT) have been studied, the prognostic value of histologic subtype in these patients remains unclear.

    OBJECTIVE: We analyzed the impact of histologic subtype on cancer-specific survival (CSS).

    DESIGN, SETTINGS, AND PARTICIPANTS: We retrospectively analyzed the records of 1774 patients with RCC and TT who underwent radical nephrectomy and tumor thrombectomy from 1971 to 2012 at 22 US and European centers.

    OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable ordered logistic and Cox regression models were used to quantify the impact of tumor histology on CSS.

    RESULTS AND LIMITATIONS: Overall 5-yr CSS was 53.4% (confidence interval [CI], 50.5-56.2) in the entire group. TT level (according to the Mayo classification of macroscopic venous invasion in RCC) was I in 38.5% of patients, II in 30.6%, III in 17.3%, and IV in 13.5%. Histologic subtypes were clear cell renal cell carcinoma (cRCC) in 89.9% of patients, papillary renal cell carcinoma (pRCC) in 8.5%, and chromophobe RCC in 1.6%. In univariable analysis, pRCC was associated with a significantly worse CSS (p<0.001) compared with cRCC. In multivariable analysis, the presence of pRCC was independently associated with CSS (hazard ratio: 1.62; CI, 1.01-2.61; p<0.05). Higher TT level, positive lymph node status, distant metastasis, and fat invasion were also independently associated with CSS.

    CONCLUSIONS: In our multi-institutional series, we found that patients with pRCC and vena cava TT who underwent radical nephrectomy and tumor thrombectomy had significantly worse cancer-specific outcomes when compared with patients with other histologic subtypes of RCC. We confirmed that higher TT level and fat invasion were independently associated with reduced CSS.


    Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

    KEYWORDS: Clear cell, Histology, Papillary, Prognosis, Renal cell carcinoma, Survival, Vena cava tumor thrombus

    Publikations ID: 23871402
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt